Attenuating DNA damage response and immunosuppression radiosensitizes pancreatic cancer.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a most devastating disease with the worst 5-year survival among all cancers in the US of around 10%.1 Surgery is the only curative treatment for pancreatic cancer patients. However, less than 15% of patients are eligible for surgery upon diagnosis since the majority are already in the advanced stage. Neoadjuvant therapies, including chemotherapy and radiotherapy aim to shrink or restrain the tumours, have shown promise in borderline resectable or metastatic PDAC patients.